Research programme: poly(ADP-ribose) polymerase 1 inhibitors - Chongqing Fochon Pharmaceutical
Alternative Names: Research programme: PARP1 inhibitors - Chongqing Fochon PharmaceuticalLatest Information Update: 27 Jan 2023
At a glance
- Originator Chongqing Fochon Pharmaceutical
- Class Antineoplastics; Small molecules
- Mechanism of Action Poly(ADP-ribose) polymerase-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 29 Nov 2022 Early research in Cancer in China (unspecified route), (Chongqing Fochon Pharmaceutical pipeline, November 2022)